fig2

Figure 2. Schematic representation of main therapeutic targets, drugs and signaling pathways for intrahepatic cholangiocarcinoma in 2023. The next generation sequencing is recommended to define the genomic aberration status before systemic therapy for unresectable or metastatic patients. The altered gene textbox highlighted in green indicates that targeted monotherapy, such as anti-NTRK^Fus or anti-RET^Fus, is recommended by NCCN in first-line or subsequent-line settings. Accordingly, the gene textbox highlighted in red means that targeted therapy alone, such as anti-FGFR2^Fus, anti-IDH1^Mut, anti-HER2^Amp, or anti-BRAF^V600E, is recommended only after front-line systemic therapy. All the targeted agents recommended in the NCCN guideline of BTC (version 2. 2023) are displayed in bold for better individualized drug selection. IDH1/2^Mut: isocitrate dehydrogenase-1/2 mutation; FGFR2^Fus: fibroblast growth factor receptor 2 fusion; HER2^Amp: human epidermal growth factor 2 amplification; BRAF^V600E: BRAF V600E mutation; NTRK^Fus: NTRK fusion; RET^Fus: RET fusion.